For Research Use Only
CNV+ Breast Cancer NGS Panel:
The CNV+ Breast Cancer NGS Panel covers 84 frequently mutated cancer hotspots in 14 genes and CNVs of 18 genes including HER2, amplified in 10-20% of breast cancers and guide treatment with trastuzumab (HERCEPTIN).
The CNV+ Breast Cancer NGS Panel utilizes unique molecular identifiers(UMI) and PCR to accurately quantify SNVs and Indels down to 0.2% VAF as well as detect CNVs in HER2 above 2.04 copies and below 1.97 copies from cfDNA.
Unlike FISH, the CNV+ Breast Cancer NGS Panel can detect hotspot mutations in 14 genes and HER2 CNVs simultaneously in the same reaction. Amplicons all along HER2 allow for ultrafine CNV mapping with sub-gene level identification of CNVs.
The CNV+ Breast Cancer NGS Panel has a high conversion yield (median >60%) allowing sensitive detection from small sample inputs (30ng FFPE DNA, 8ng fresh/frozen DNA, 10ng cfDNA).